UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
NVCT holding history
Nuvectis Pharma, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NVCT overviewAll 13F holders of NVCTFull Q2 2026 holdings
- Shares (Q2 2026)
- 69,200
- Value
- $1.27M
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q1 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 69,200 | $1.27M | <0.1% | +30,637+79.4% | Added | Holders |
| Q1 2026 | 38,563 | $298.1K | <0.1% | +30,188+360.5% | Added | Holders |
| Q4 2025 | 8,375 | $63.2K | <0.1% | −17,094−67.1% | Reduced | Holders |
| Q3 2025 | 25,469 | $153.3K | <0.1% | +15,211+148.3% | Added | Holders |
| Q2 2025 | 10,258 | $76.6K | <0.1% | −101,262−90.8% | Reduced | Holders |
| Q1 2025 | 111,520 | $1.09M | <0.1% | +108,851+4,078.3% | Added | Holders |
| Q4 2024 | 2,669 | $14.4K | <0.1% | +2,658+24,163.6% | Added | Holders |
| Q3 2024 | 11 | $69 | <0.1% | −2−15.4% | Reduced | Holders |
| Q2 2024 | 13 | $82 | <0.1% | −7,607−99.8% | Reduced | Holders |
| Q1 2024 | 7,620 | $62.5K | <0.1% | −440−5.5% | Reduced | Holders |
| Q4 2023 | 8,060 | $67.2K | <0.1% | +4,284+113.5% | Added | Holders |
| Q3 2023 | 3,776 | $48.7K | <0.1% | −203−5.1% | Reduced | Holders |
| Q2 2023 | 3,979 | $63.5K | <0.1% | +3,979 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −220−100.0% | Sold out | Holders |
| Q3 2022 | 220 | $2.00K | <0.1% | +158+254.8% | Added | Holders |
| Q2 2022 | 62 | $1.00K | <0.1% | −79−56.0% | Reduced | Holders |
| Q1 2022 | 141 | $1.00K | <0.1% | +141 | New | Holders |